Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Almirall Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Almirall wird ein jährliches Gewinn- und Umsatzwachstum von 48.4% bzw. 9.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 1.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 6.6% betragen.

Wichtige Informationen

49.4%

Wachstumsrate der Gewinne

1.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	25.4%
Wachstumsrate der Einnahmen	9.5%
Zukünftige Eigenkapitalrendite	6.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	07 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05

Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 15

Almirall, S.A. (BME:ALM) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 02

Would Shareholders Who Purchased Almirall's (BME:ALM) Stock Five Years Be Happy With The Share price Today?

Jan 20

Gewinn- und Umsatzwachstumsprognosen

BME:ALM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,207	102	160	242	8
12/31/2025	1,078	61	103	197	9
12/31/2024	979	25	66	152	7
3/31/2024	915	-39	-48	116	N/A
12/31/2023	899	-38	-66	93	N/A
9/30/2023	907	7	-23	101	N/A
6/30/2023	898	-11	23	156	N/A
3/31/2023	882	-8	37	154	N/A
12/31/2022	879	4	39	155	N/A
9/30/2022	864	9	105	177	N/A
6/30/2022	856	29	98	180	N/A
3/31/2022	843	-50	82	159	N/A
12/31/2021	837	-41	163	234	N/A
9/30/2021	814	-22	204	288	N/A
6/30/2021	809	-11	145	196	N/A
3/31/2021	790	55	122	198	N/A
12/31/2020	814	74	36	113	N/A
9/30/2020	849	63	72	212	N/A
6/30/2020	872	86	49	194	N/A
3/31/2020	926	121	158	296	N/A
12/31/2019	911	106	141	276	N/A
9/30/2019	858	85	-410	190	N/A
6/30/2019	884	88	-368	181	N/A
3/31/2019	789	80	-463	138	N/A
12/31/2018	811	78	-456	143	N/A
9/30/2018	714	-111	105	170	N/A
6/30/2018	730	-179	10	133	N/A
3/31/2018	687	-293	16	82	N/A
12/31/2017	677	-304	N/A	6	N/A
9/30/2017	735	-128	N/A	-89	N/A
6/30/2017	755	-78	N/A	-13	N/A
3/31/2017	821	73	N/A	12	N/A
12/31/2016	822	75	N/A	105	N/A
9/30/2016	778	162	N/A	151	N/A
6/30/2016	743	154	N/A	122	N/A
3/31/2016	721	111	N/A	114	N/A
12/31/2015	738	132	N/A	171	N/A
9/30/2015	783	479	N/A	761	N/A
6/30/2015	802	488	N/A	748	N/A
3/31/2015	842	481	N/A	768	N/A
12/31/2014	828	448	N/A	647	N/A
9/30/2014	868	-13	N/A	56	N/A
6/30/2014	849	-32	N/A	52	N/A
3/31/2014	845	-33	N/A	62	N/A
12/31/2013	825	-34	N/A	67	N/A
9/30/2013	805	7	N/A	40	N/A
6/30/2013	889	67	N/A	90	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.5%).

Ertrag vs. Markt: ALM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ALM wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ALMDie Einnahmen des Unternehmens (9.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Spanish (4.4% pro Jahr).

Hohe Wachstumseinnahmen: ALMDie Einnahmen des Unternehmens (9.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ALMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (6.6 %).

Almirall Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Consensus EPS estimates increase by 29%

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 26%

Recent updates

Dividend of €0.15 announced

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Almirall, S.A., Annual General Meeting, May 10, 2024

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 29%

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Now 21% undervalued

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

New minor risk - Shareholder dilution

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

New minor risk - Dividend sustainability

Is Almirall (BME:ALM) A Risky Investment?

First quarter 2023 earnings released

Consensus EPS estimates fall by 26%

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued after recent price drop

Price target decreased by 7.2% to €11.93

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Now 20% undervalued

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings: EPS misses analyst expectations

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Now 21% undervalued

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Now 22% undervalued

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Price target decreased to €14.66

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020)

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis

First quarter 2021 earnings released: EPS €0.17 (vs €0.28 in 1Q 2020)

Consensus forecasts updated

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

New 90-day high: €12.19